IQVIA (IQV) has collaborated with AstraZeneca (AZN.L, AZN) to accelerate development of a potential new vaccine for COVID-19. The collaboration will drive faster delivery of clinical studies in the U.S. of AstraZeneca's potential COVID-19 vaccine, AZD1222. The joint initiative is part of the U.S. government's Operation Warp Speed project.

Create Account

Dark

chart

exchange

RTTNews | Jul 14, 2020 08:13AM EDT

08:13 Tuesday, July 14, 2020 (RTTNews.com) - IQVIA (IQV) has collaborated with AstraZeneca (AZN.L, AZN) to accelerate development of a potential new vaccine for COVID-19. The collaboration will drive faster delivery of clinical studies in the U.S. of AstraZeneca's potential COVID-19 vaccine, AZD1222. The joint initiative is part of the U.S. government's Operation Warp Speed project.

IQVIA is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The collaboration initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and will leverage IQVIA's Virtual Trial solutions including Study Hub.

Read the original article on RTTNews ( https://www.rttnews.com/3110844/iqvia-astrazeneca-join-to-accelerate-development-of-potential-covid-19-vaccine.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved